2020 American Society of Hematology Virtual Annual Meeting*

New data for CC-486 maintenance therapy in AML support a new escalated 21-day dosing schedule for patients who experience relapse with ≤ 15% blasts and an overall preservation of health-related quality of life.

FLT3 inhibitor gilteritinib combined with induction and consolidation chemotherapy was well tolerated and showed good response in final results from this phase I study of patients with newly diagnosed FLT3-mutated acute myeloid leukemia.

The combination of magrolimab plus azacytidine was associated with rapid, deep responses with little added toxicity, including in patients with the TP53 mutation.

In a phase I/II trial, flotetuzumab showed encouraging activity and a manageable safety profile in patients with AML and primary induction failure or early relapse.

Hyper-CVAD + blinatumomab shows promising activity with both high response rates and deep responses in patients with newly diagnosed B-cell ALL in this phase II study.

In an interim analysis of the randomized phase II OPTIC trial, the maximum benefit:risk ratio with ponatinib was observed with 45-mg starting dose in previously treated CP-CML regardless of mutation status or number of previous TKIs.

Ponatinib treatment in patient with chronic-phase chronic myeloid leukemia who progressed after second-generation TKIs showed efficacy and tolerability in this pooled analysis of the PACE and OPTIC trials.

Twice-daily asciminib was associated with a major molecular response rate of 46.9% in pretreated patients with T315I-mutated CML, including those previously treated with ponatinib.

Oral AZA (CC-486) significantly improved OS and RFS in patients with CR/CRi AML regardless of baseline MRD status, although baseline MRD positivity showed reduced benefit.

At Week 24, asciminib significantly improved MMR rate compared with bosutinib (25.5% vs 13.2%, respectively) with numerically lower rates of AEs leading to discontinuation, dose adjustment, or the requirement for additional therapy.